Loading
Latest filing published 11 Feb 2022 for Turning Point Therapeutics, Inc., €21k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
All filings by Annette North on record concern Turning Point Therapeutics, Inc., in the capacity of senior executive. Over a trading history stretching from 6 May 2021 to 9 February 2022, the count stands at 4 filings.
The open-market record consists of 1 sale worth €21k, with no purchase. Outside the open market, there are 3 option exercises. So far in 2022, the count stands at no purchases and 1 sale.
On 11 February 2022 came the latest disclosure, an open-market sale for €21k in Turning Point Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 1 day. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations